TB-500 is a synthetic peptide corresponding to the active region of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant intracellular peptides in mammalian cells. Thymosin beta-4 was originally isolated from the thymus gland and was initially studied for its role in T-cell maturation. Subsequent research revealed that its primary biological function relates to actin cytoskeleton regulation, and it has since been investigated in preclinical models across multiple tissue types for its role in cell migration and tissue repair processes.
What Is TB-500?
TB-500 refers to a synthetic peptide fragment encompassing the active domain of thymosin beta-4, centered on the actin-binding motif with the sequence LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln). This heptapeptide sequence is responsible for the actin-sequestering activity of the full-length protein. The synthetic fragment used in research maintains this core functional domain while being more practical to synthesize at research-grade purity than the full 43-amino-acid protein.
Thymosin beta-4 itself has a molecular weight of approximately 4,921 Daltons and is found at high concentrations in blood platelets, wound fluid, and virtually all nucleated cells. It is released from cells in response to tissue damage signals, where it participates in the initial stages of the tissue repair cascade.
Actin Regulation Research
The best-characterized molecular function of thymosin beta-4 is its role as the primary intracellular buffer for monomeric actin (G-actin). By sequestering G-actin in a 1:1 complex, thymosin beta-4 regulates the pool of actin monomers available for polymerization into filamentous actin (F-actin). This regulation of the G-actin/F-actin equilibrium is fundamental to cell motility, division, and morphological changes.
In-vitro studies have demonstrated that the LKKTETQ motif of TB-500 is both necessary and sufficient for G-actin binding. Researchers studying cytoskeletal dynamics have used TB-500 as a tool to modulate actin polymerization in cell culture systems. By altering the availability of monomeric actin, TB-500 affects downstream processes including lamellipodium formation, cell spreading, and directional migration.
Cell Migration and Angiogenesis Research
Preclinical studies have investigated the effects of TB-500 on cell migration using standard in-vitro assays including the scratch wound assay and Boyden chamber migration assay. In these studies, endothelial cells, keratinocytes, and fibroblasts treated with TB-500 demonstrated increased migration rates compared to untreated controls. The proposed mechanism involves promotion of actin reorganization at the leading edge of migrating cells.
Angiogenesis research has also been a significant area of TB-500 investigation. In-vitro tube formation assays using human umbilical vein endothelial cells (HUVECs) have demonstrated that TB-500 promotes capillary-like network formation. Animal model studies using corneal micropocket assays and Matrigel plug assays have provided additional evidence of pro-angiogenic activity in vivo. These observations have been attributed to both direct effects on endothelial cell migration and indirect effects through modulation of angiogenic growth factors.
Preclinical Wound and Tissue Research
TB-500 has been studied in several animal models of tissue injury. In rodent models of dermal wounding, TB-500 administration was associated with accelerated wound closure, increased collagen deposition, and enhanced angiogenesis in wound beds as assessed by histological analysis. Similar studies in models of corneal injury, cardiac injury following ischemia-reperfusion, and skeletal muscle damage have reported comparable findings of enhanced tissue repair parameters in treated groups.
It is important to note that these results have been obtained exclusively in preclinical models. The mechanisms proposed to underlie these observations include promotion of cell migration into the injury site, modulation of inflammatory cell infiltration, upregulation of extracellular matrix deposition, and enhancement of new blood vessel formation. The relative contribution of each mechanism likely varies by tissue type and injury model.
Storage and Handling
TB-500 is supplied as a lyophilized white powder. For long-term storage, it should be maintained at negative twenty degrees Celsius, where it is stable for twelve months or longer. Reconstitution is typically performed using bacteriostatic water, producing a clear solution. After reconstitution, the peptide should be stored at two to eight degrees Celsius and used within three to four weeks. Aliquoting into single-use volumes is recommended to prevent degradation from repeated freeze-thaw cycles.
Research Use Notice
TB-500 is sold exclusively as a research chemical for in-vitro and preclinical research purposes. It is not approved for human consumption, veterinary therapeutic use, or clinical application. All findings described in this article are derived from cell culture and animal model studies. Researchers must ensure compliance with all applicable regulatory and institutional guidelines when using TB-500 in their experimental protocols.